Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

WATERTOWN, Mass., May 11 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.  The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer's disease patients.

"Patients with Alzheimer's disease have a number of symptomatic therapies available to them. However, the effects of the available medications are modest. Even if significant progress is made in slowing disease progression, more effective therapies that sustainably improve the cognition of the patients are clearly needed," said Kees Been, EnVivo president and CEO. "There is growing consensus that alpha-7 nicotinic agonists can potentially improve the cognitive function in Alzheimer's disease patients as evidenced by the number of large pharmaceutical companies advancing similar drugs through development. The potential upside for patients is considerable and we look forward to completing our Alzheimer's disease study by the middle of next year."

The Phase IIb study will enroll mild to moderate Alzheimer's disease patients who will be randomized to three separate doses of EVP-6124 or placebo over six months. Efficacy will primarily be determined by the ADAS-Cog scale, a commonly used and accepted measure of cognition in patients with Alzheimer's disease. Secondary assessments will include other cognitive and clinical measures. EVP-6124 also is being tested in patients with schizophrenia in a separate Phase IIb study that started in late 2009
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the ... President of Managed Care. In this role, Damm will ... the nation’s leading specialty pharmacies. , Damm, who is ... specialty pharmacy and biotech experience to his new position ... Pharmaceuticals, and Pfizer. Prior to working in Healthcare Damm ...
(Date:3/5/2015)... 05, 2015 Research and Markets ( ... "Mature Biotech Outlook 2015: New Therapy Ventures Pave the ... All biotech companies - Gilead (GILD), Amgen ... year, have given a positive return and hence increased ... able to select therapy/niche indication where the high treatment ...
(Date:3/4/2015)... 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the: , 3.75% Convertible Senior Notes due May ... stock per $1,000 principal amount or approximately $5.72 per share, ... the note is adjusted in connection with the regular quarterly ... all stockholders who own shares of PDL on March 5, 2015, ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3
... of partner clinics, fits dozens ... ... /PRNewswire/ - Touch,Bionics, developer of the world,s first commercially available bionic ... Currently basing U.S. operations out of Boston, MA, this announcement,follows the ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading developer ... treatment systems, today announced that the company,will host ... on Tuesday,February 12, 2008 at 9:00 a.m. ET., ... Officer Michael Davin and,Executive Vice President and Chief ...
... Ga. and RESEARCH TRIANGLE PARK, N.C., Jan. 29 ,Merial ... signed an,agreement under which Merial will screen a Chimerix ... of this agreement, Merial has an,option to negotiate a ... use., "This collaboration with Chimerix provides us with ...
Cached Biology Technology:Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 2Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 3Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 4Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12 2Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and ... and Voice Biometrics. The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , ... and Latin America . Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/23/2015)... OXFORD, Conn. , Feb. 23, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62114357 for ... With this patent, NXT-ID introduces a new groundbreaking payment ... and the payment account may only be accessed if ...
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2
... Researchers at Huntsman Cancer Institute (HCI) at the University ... often deadly bone cancer that typically afflicts children and young ... tumors with high levels of a protein known as GSTM4, ... published online today in the journal Oncogene . ...
... of Oceanography at UC San Diego and their colleagues ... structure of a naturally produced, ocean-based compound that is ... cells. The findings are reported in the Aug. ... Biology by principal co-investigators William Gerwick, professor of ...
... (August 28, 2009)The American Phytopathological Society (APS) is proud ... Scientist, is the recipient of the 2009 Plant Pathology ... Green Menace," published in the March 13, 2008, issue ... Green Menace," Callaway discussed the citrus disease huanglongbinga bacterial ...
Cached Biology News:New hope for deadly childhood bone cancer 2Marine biomedicine researchers decode structure of promising sea compound 2Ewen Callaway named 2009 APS Plant Pathology Journalism awardee 2
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Evolutionarily conserved signaling intermediate in Toll pathway...
Biology Products: